Diagnosis of myocardial infarction in record time
Development of a lateral flow device for early diagnosis of myocardial infarction.
Healthsens is currently developing a useful rapid test for the specific and early diagnosis of myocardial infarction. Using a lateral flow strip, patients will be able to know quickly if they are having a heart attack.
Healthsens is committed to developing a lateral flow assay (LFA) that will be able to detect heart troponin in a drop of blood, a specific biomarker of myocardial infarction and the pathological heart condition that is released into the bloodstream when heart damage occurs.
Cardiac troponin consists of three subunits (troponin I, C, T), with subunit I being the one with the greatest clinical interest. This subunit is specifically associated with myocardial infarction and coronary/arterial disease. The determination of troponin I, in conjunction with the clinical evaluation of the patient, is used to stratify the risk of a heart attack or coronary/arterial disease in people who have chest pain or symptoms of cardiovascular disease. Healthsens TropoStrip will allow the detection of troponin I quickly and easily in a drop of total blood.
Nowadays, the available assays used to measure cardiac troponin I, while providing adequate diagnostic performance, present several drawbacks. These include the need for highly specialized personnel to carry out a venous blood sample and its subsequent analysis through time-consuming laboratory techniques or bulky devices. These tools are also very expensive and require constant maintenance. A device such as Healthsens TropoStrip, reduces costs from the beginning and can be used easily not only in modern clinics and hospitals, but also in the most disadvantaged contexts (rural or isolated areas, developing countries, war zones, etc.) as it is a practical, chemically stable device capable of quickly providing an accurate result in record time compared to conventional methodologies used in clinic for the determination of Troponin I.
Healthsens TropoStrip will be a compact and practical device capable of providing meaningful clinical information in minutes. The goal of Healthsens is to develop an economical and easy-to-use device that can be used in any place, significantly reducing waiting times and facilitating proper intervention.
The cardiac troponin I biomarker is highly specific to myocardial infarction.
Cardiovascular disease is currently the leading cause of death worldwide.
Ischemic heart disease and heart attack are responsible for 16% and 11% of all annual deaths in the world, respectively.
In 2019, 8.9 million deaths are attributed to ischemic heart disease (IHD).